Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 81Neoplasm Metastasis 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Multiple Myeloma 4HER2-positive Breast Cancer 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Hematologic Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Lymphoma 2Lung Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Urologic Neoplasms 1Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Thyroid Neoplasms 1Thrombocytosis 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Carboplatin 4Sunitinib 3Pemetrexed 3Mitomycin 3cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urologic Neoplasms × Ado-Trastuzumab Emtansine × Clear all
NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
131 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡